Please use this identifier to cite or link to this item:
Title: Gut microbiota - a double-edged sword in cancer immunotherapy.
Austin Authors: Andrews, Miles C;Vasanthakumar, Ajithkumar
Affiliation: Department of Medicine - Alfred, Monash University, Melbourne, Victoria, Australia.
Olivia Newton-John Cancer Research Institute
La Trobe University, Bundoora, Victoria, Australia
Issue Date: 2023
Date: 2022
Publication information: Trends in Cancer 2023; 9(1)
Abstract: Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes.
DOI: 10.1016/j.trecan.2022.08.003
Journal: Trends in Cancer
PubMed URL: 36088249
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.